Abl

ABL family kinases, including ABL1 (c-Abl) and ABL2 (Arg), are non-receptor tyrosine kinases that integrate cytoskeletal regulation, cell adhesion, migration, endocytosis, proliferation, and stress-response signaling across multiple cellular contexts^[1][1]. Mechanistically, ABL kinases couple SH3-SH2-SH1 signaling modules with actin-binding domains, enabling regulation of cytoskeletal remodeling and cell motility pathways that influence tissue morphogenesis and cellular invasion^[1][2]. In disease settings, aberrant ABL kinase activation contributes to hematologic malignancies through oncogenic fusion proteins such as BCR-ABL1, while increased endogenous ABL signaling has also been reported in solid tumors, including breast, colorectal, melanoma, lung, and renal cancers^[2][3]. Compared with ABL1, which contains nuclear localization and DNA-binding elements linked to stress-response and nuclear signaling functions, ABL2 is enriched in cytoplasmic and peripheral cytoskeletal compartments and plays a prominent role in invadopodia maturation, tumor-cell invasion, and metastatic dissemination^[1][2]. For experimental applications, ATP-competitive inhibitors such as imatinib, nilotinib, and dasatinib, together with selective allosteric ABL inhibitors targeting the myristoyl-binding pocket, are widely used to dissect ABL-dependent signaling networks and evaluate kinase-driven disease mechanisms^[1][3].